棘白菌素对念珠菌属的体外矛盾效应：棘白菌素特异性及念珠菌属相关差异的证据
Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differences.
作者信息
Chamilos Georgios, Lewis Russell E, Albert Nathaniel, Kontoyiannis Dimitrios P
机构信息
Department of Infectious Diseases, Infection Control and Employee Health, Unit 402, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
出版信息
Antimicrob Agents Chemother. 2007 Jun;51(6):2257-9. doi: 10.1128/AAC.00095-07. Epub 2007 Apr 16.
Abstract
Paradoxical growth of some Candida isolates occurs at concentrations above the MIC for echinocandins. In 60 Candida bloodstream isolates from cancer patients (20 C. albicans isolates and 10 isolates each of C. parapsilosis, C. tropicalis, C. krusei, and C. glabrata), paradoxical growth was more frequent with caspofungin than micafungin or anidulafungin, was unrelated to MIC, and was strikingly absent in C. glabrata isolates.
摘要
一些念珠菌分离株在高于棘白菌素最低抑菌浓度（MIC）的浓度下会出现反常生长。在从癌症患者中分离出的60株念珠菌血流感染菌株（20株白色念珠菌分离株以及近平滑念珠菌、热带念珠菌、克柔念珠菌和光滑念珠菌各10株分离株）中，卡泊芬净导致的反常生长比米卡芬净或阿尼芬净更常见，与最低抑菌浓度无关，且在光滑念珠菌分离株中明显不存在。
相似文献
1
Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differences.
Antimicrob Agents Chemother. 2007 Jun;51(6):2257-9. doi: 10.1128/AAC.00095-07. Epub 2007 Apr 16.
2
Species-specific differences in the susceptibilities of biofilms formed by Candida bloodstream isolates to echinocandin antifungals.
Antimicrob Agents Chemother. 2007 Apr;51(4):1520-3. doi: 10.1128/AAC.01141-06. Epub 2007 Feb 5.
3
In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole.
J Clin Microbiol. 2005 Nov;43(11):5425-7. doi: 10.1128/JCM.43.11.5425-5427.2005.
4
Micafungin activity against Candida bloodstream isolates: effect of growth medium and susceptibility testing method.
Diagn Microbiol Infect Dis. 2007 May;58(1):129-32. doi: 10.1016/j.diagmicrobio.2006.10.017. Epub 2007 Jan 19.
5
Echinocandin susceptibility testing of Candida isolates collected during a 1-year period in Sweden.
J Clin Microbiol. 2011 Jul;49(7):2516-21. doi: 10.1128/JCM.00201-11. Epub 2011 May 4.
6
Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.
J Clin Microbiol. 2006 Feb;44(2):324-6. doi: 10.1128/JCM.44.2.324-326.2006.
7
National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
J Antimicrob Chemother. 2004 Feb;53(2):283-9. doi: 10.1093/jac/dkh053. Epub 2003 Dec 19.
8
Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods.
J Clin Microbiol. 2006 Oct;44(10):3533-8. doi: 10.1128/JCM.00872-06.
9
Multicenter surveillance of species distribution and antifungal susceptibilities of Candida bloodstream isolates in South Korea.
Med Mycol. 2010 Jun;48(4):669-74. doi: 10.3109/13693780903410386.
10
In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance.
J Clin Microbiol. 2006 Mar;44(3):760-3. doi: 10.1128/JCM.44.3.760-763.2006.
引用本文的文献
1
Distinct echinocandin responses of Candida albicans and Candida auris cell walls revealed by solid-state NMR.
Nat Commun. 2025 Jul 8;16(1):6295. doi: 10.1038/s41467-025-61678-1.
2
Antifungal Susceptibility Testing - The Times They Are a Changin'.
Clin Microbiol Newsl. 2019 May 15;41(10):85-90. doi: 10.1016/j.clinmicnews.2019.04.006.
3
A screen to identify antifungal antagonists reveals a variety of pharmacotherapies induce echinocandin tolerance in .
bioRxiv. 2025 Feb 19:2025.02.18.638903. doi: 10.1101/2025.02.18.638903.
4
Molecular Mechanisms Associated with Antifungal Resistance in Pathogenic Species.
Cells. 2023 Nov 19;12(22):2655. doi: 10.3390/cells12222655.
5
Candida species causing fungal keratitis: molecular identification, antifungal susceptibility, biofilm formation, and clinical aspects.
Braz J Microbiol. 2023 Jun;54(2):629-636. doi: 10.1007/s42770-023-00964-w. Epub 2023 Apr 13.
6
Genomic and Molecular Identification of Genes Contributing to the Caspofungin Paradoxical Effect in .
Microbiol Spectr. 2022 Oct 26;10(5):e0051922. doi: 10.1128/spectrum.00519-22. Epub 2022 Sep 12.
7
Early Empirical Anidulafungin Reduces the Prevalence of Invasive Candidiasis in Critically Ill Patients: A Case-control Study.
J Crit Care Med (Targu Mures). 2022 May 12;8(2):89-99. doi: 10.2478/jccm-2022-0006. eCollection 2022 Apr.
8
Echinocandins - structure, mechanism of action and use in antifungal therapy.
J Enzyme Inhib Med Chem. 2022 Dec;37(1):876-894. doi: 10.1080/14756366.2022.2050224.
9
Adaptation of the emerging pathogenic yeast to high caspofungin concentrations correlates with cell wall changes.
Virulence. 2021 Dec;12(1):1400-1417. doi: 10.1080/21505594.2021.1927609.
10
Epithelial Infection With Elicits a Multi-System Response in Planarians.
Front Microbiol. 2021 Jan 14;11:629526. doi: 10.3389/fmicb.2020.629526. eCollection 2020.
本文引用的文献
1
Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species.
Antimicrob Agents Chemother. 2007 Mar;51(3):881-7. doi: 10.1128/AAC.01160-06. Epub 2006 Dec 4.
2
Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin.
Antimicrob Agents Chemother. 2006 Sep;50(9):3160-1. doi: 10.1128/AAC.00563-06.
3
Assessment of the paradoxical effect of caspofungin in therapy of candidiasis.
Antimicrob Agents Chemother. 2006 Apr;50(4):1293-7. doi: 10.1128/AAC.50.4.1293-1297.2006.
4
Attenuation of the activity of caspofungin at high concentrations against candida albicans: possible role of cell wall integrity and calcineurin pathways.
Antimicrob Agents Chemother. 2005 Dec;49(12):5146-8. doi: 10.1128/AAC.49.12.5146-5148.2005.
5
Characterization of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin.
Med Mycol. 2005 May;43 Suppl 1:S299-305. doi: 10.1080/13693780400029023.
6
In vitro activity of caspofungin compared to amphotericin B, fluconazole, and itraconazole against Candida strains isolated in a Turkish University Hospital.
Med Mycol. 2005 Mar;43(2):171-8. doi: 10.1080/13693780410001731565.
7
Studies of the paradoxical effect of caspofungin at high drug concentrations.
Diagn Microbiol Infect Dis. 2005 Mar;51(3):173-8. doi: 10.1016/j.diagmicrobio.2004.10.006.
8
Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis.
Antimicrob Agents Chemother. 2005 Feb;49(2):767-9. doi: 10.1128/AAC.49.2.767-769.2005.
9
Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity.
J Infect Dis. 2004 Oct 15;190(8):1464-71. doi: 10.1086/424465. Epub 2004 Sep 10.
10
Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations.
Antimicrob Agents Chemother. 2004 Sep;48(9):3407-11. doi: 10.1128/AAC.48.9.3407-3411.2004.
Zotero 插件